NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Maravai LifeSciences Holdings, Inc. (MRVI) Stock Analysis

Maravai LifeSciences Holdings, Inc. (MRVI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MRVI

$7.32

−$0.05 (−0.68%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MRVI with… →

MRVI Key Statistics

As of Sep 4, 2026
Trading
Open
$7.25
Previous Close
$7.37
Day's Range
7.17–7.44
52-Week Range
2.42–9.42
Volume
1.55M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.60
Valuation
Market Cap
$2.71B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
12.99
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.53
Financials (FY)
Revenue (FY)
$185.74M−28.34%
Net Income (FY)
−$130.77M
Profit marginThe share of revenue left as profit after all costs and taxes.
−37.07%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
148.99M
1-Year Return
+210.17%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
3.52M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MRVI Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+125.23%
2025−40.37%
2024−16.79%
2023−54.23%
2022−65.85%
2021+49.38%
2020 (partial year)−6.03%

As of September 4, 2026.

MRVI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$185.74M−$130.77M−70.4%
2024$259.19M−$144.85M−55.9%
2023$288.95M−$119.03M−41.2%
2022$883.00M$220.21M24.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$185.74M$33.99M−$128.53M−$130.77M−70.4%
2024$259.19M$108.31M−$72.68M−$144.85M−55.9%
2023$288.95M$140.20M−$28.47M−$119.03M−41.2%
2022$883.00M$714.04M$566.42M$220.21M24.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MRVI Valuation vs Biotechnology Median

Median of 656 stocks
MetricMRVIBiotechnology medianvs median
P/S ratio12.9915.2615% below
Profit margin−37.07%0.00%37.1 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Maravai LifeSciences Holdings, Inc. (MRVI) at $2.71B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 415 employees.

The most recent close on file for MRVI is $7.32, dated September 4, 2026. That is −$0.05 (−0.68%) against the previous close. Over the past 52 weeks the price has ranged from $2.42 to $9.42. The latest close sits 202.48% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $185.74M. Against the prior fiscal year total of $259.19M, that is a change of −28.34%. The same year closed with a net loss of $130.77M. The reported profit margin is −37.07%. That is 37.1 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −0.53.

Across the 4 fiscal years on file, revenue moves from $883.00M in 2022 to $185.74M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 12.99. On price-to-sales that is 14.93% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +210.17%. Measured over 5 years, that is −34.04% a year compounded. Beta against the wider market is reported at 0.61. Annualized volatility over the trailing 5 years is 75.85%.

Growth & Income

The record shows no dividend for MRVI.

Across the complete calendar years on file, 2021 returned +49.38% and 2022 returned −65.85%. Of the 5 complete calendar years on file, 1 finished higher. So far in 2026 the price is +125.23%.

Peer Comparison

Maravai LifeSciences Holdings, Inc. (MRVI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Maravai LifeSciences Holdings, Inc. MRVI $2.71B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Maravai LifeSciences Holdings, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Maravai LifeSciences Holdings, Inc.

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

Visit website →